Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells
Leukemic stem cells which are resistant to chemotherapy are proposed as relapse-initiating cells (RICs). Here, the authors show that targeting the adrenomedullin-calcitonin receptor-like receptor decreases RICs frequency improving chemotherapy response in AML preclinical models.
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-01-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-020-20717-9 |
| _version_ | 1818436042054696960 |
|---|---|
| author | Clément Larrue Nathan Guiraud Pierre-Luc Mouchel Marine Dubois Thomas Farge Mathilde Gotanègre Claudie Bosc Estelle Saland Marie-Laure Nicolau-Travers Marie Sabatier Nizar Serhan Ambrine Sahal Emeline Boet Sarah Mouche Quentin Heydt Nesrine Aroua Lucille Stuani Tony Kaoma Linus Angenendt Jan-Henrik Mikesch Christoph Schliemann François Vergez Jérôme Tamburini Christian Récher Jean-Emmanuel Sarry |
| author_facet | Clément Larrue Nathan Guiraud Pierre-Luc Mouchel Marine Dubois Thomas Farge Mathilde Gotanègre Claudie Bosc Estelle Saland Marie-Laure Nicolau-Travers Marie Sabatier Nizar Serhan Ambrine Sahal Emeline Boet Sarah Mouche Quentin Heydt Nesrine Aroua Lucille Stuani Tony Kaoma Linus Angenendt Jan-Henrik Mikesch Christoph Schliemann François Vergez Jérôme Tamburini Christian Récher Jean-Emmanuel Sarry |
| author_sort | Clément Larrue |
| collection | DOAJ |
| description | Leukemic stem cells which are resistant to chemotherapy are proposed as relapse-initiating cells (RICs). Here, the authors show that targeting the adrenomedullin-calcitonin receptor-like receptor decreases RICs frequency improving chemotherapy response in AML preclinical models. |
| first_indexed | 2024-12-14T17:02:29Z |
| format | Article |
| id | doaj.art-e5db0cc7b23d4c7f80b655c467b00921 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-12-14T17:02:29Z |
| publishDate | 2021-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-e5db0cc7b23d4c7f80b655c467b009212022-12-21T22:53:49ZengNature PortfolioNature Communications2041-17232021-01-0112111510.1038/s41467-020-20717-9Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cellsClément Larrue0Nathan Guiraud1Pierre-Luc Mouchel2Marine Dubois3Thomas Farge4Mathilde Gotanègre5Claudie Bosc6Estelle Saland7Marie-Laure Nicolau-Travers8Marie Sabatier9Nizar Serhan10Ambrine Sahal11Emeline Boet12Sarah Mouche13Quentin Heydt14Nesrine Aroua15Lucille Stuani16Tony Kaoma17Linus Angenendt18Jan-Henrik Mikesch19Christoph Schliemann20François Vergez21Jérôme Tamburini22Christian Récher23Jean-Emmanuel Sarry24Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierGeneva University Hospitals, University of GenevaCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierProteome and Genome Research Unit, Department of Oncology, Luxembourg Institute of HealthDepartment of Medicine A, University Hospital MünsterDepartment of Medicine A, University Hospital MünsterDepartment of Medicine A, University Hospital MünsterCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierGeneva University Hospitals, University of GenevaCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierCentre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul SabatierLeukemic stem cells which are resistant to chemotherapy are proposed as relapse-initiating cells (RICs). Here, the authors show that targeting the adrenomedullin-calcitonin receptor-like receptor decreases RICs frequency improving chemotherapy response in AML preclinical models.https://doi.org/10.1038/s41467-020-20717-9 |
| spellingShingle | Clément Larrue Nathan Guiraud Pierre-Luc Mouchel Marine Dubois Thomas Farge Mathilde Gotanègre Claudie Bosc Estelle Saland Marie-Laure Nicolau-Travers Marie Sabatier Nizar Serhan Ambrine Sahal Emeline Boet Sarah Mouche Quentin Heydt Nesrine Aroua Lucille Stuani Tony Kaoma Linus Angenendt Jan-Henrik Mikesch Christoph Schliemann François Vergez Jérôme Tamburini Christian Récher Jean-Emmanuel Sarry Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells Nature Communications |
| title | Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells |
| title_full | Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells |
| title_fullStr | Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells |
| title_full_unstemmed | Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells |
| title_short | Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells |
| title_sort | adrenomedullin calcrl axis controls relapse initiating drug tolerant acute myeloid leukemia cells |
| url | https://doi.org/10.1038/s41467-020-20717-9 |
| work_keys_str_mv | AT clementlarrue adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT nathanguiraud adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT pierrelucmouchel adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT marinedubois adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT thomasfarge adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT mathildegotanegre adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT claudiebosc adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT estellesaland adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT marielaurenicolautravers adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT mariesabatier adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT nizarserhan adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT ambrinesahal adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT emelineboet adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT sarahmouche adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT quentinheydt adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT nesrinearoua adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT lucillestuani adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT tonykaoma adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT linusangenendt adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT janhenrikmikesch adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT christophschliemann adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT francoisvergez adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT jerometamburini adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT christianrecher adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells AT jeanemmanuelsarry adrenomedullincalcrlaxiscontrolsrelapseinitiatingdrugtolerantacutemyeloidleukemiacells |